The competitive landscape in the chemicals sector is changing quickly - and businesses need to adapt fast.
Rapid growth in emerging markets, significant new market players and unprecedented levels of M&A are generating both challenges and opportunities for chemicals companies and those investing in the sector.
At Linklaters, we understand and can support our clients in addressing some of the key issues including:
- fast changing competitive landscape with the current M&A spike and the break-up of the traditional chemicals conglomerate
- shift in global sector economics with the supply base moving west and the demand base moving east
- extraterritorial reach of national laws which have far reaching implications for global businesses
We advise chemicals companies and those investing in the sector on a wide range of corporate, M&A and finance matters and we have a strong regulatory team who are extremely well placed to advise on sector-specific issues such as product and trade regulations.
Through our long history of advising clients in the chemicals sector and our current roles on three of the four ‘mega-mergers’ we understand how the chemicals sector works and what drives the companies operating and investing in this space. This means that we do not need to spend time getting to grips with the basic issues and are able to provide you with informed, targeted and commercial advice from the outset, saving you time and money.
To discuss legal issues with Linklaters’ global chemicals team, please contact sector leaders Dan Tyrer or Daniela Seeliger.
You can find out more about Linklaters’ chemicals capabilities from sector manager Clare Gosalves on (44 20) 7456 2608.
Recent experience includes advising:
- Bayer on the carve out of its MaterialScience business and on the IPO of the new entity Covestro
- Solvay on the US$5.5bn merger agreement with U.S. based Cytec and on the subsequent reorganisation of its corporate structure
- Mitsui on its acquisition, together with Denka, of DuPont’s global neoprene business
- Linde on the antitrust implications of various strategic industrial gas deals
- the lead managers on the bond refinancing of Bayer’s bridge financing to fund its US$66bn acquisition of Monsanto
- HSBC and other lenders on the debt financing for ChemChina on the US$43bn acquisition of Syngenta
- Sherwin-Williams on the merger filings required in the EU, Russia, Latin-America and Asia-Pacific (except China and Australia) for its acquisition of Valspar for US$11.3bn
- Alent on the £1.35bn recommended cash offer by Platform Speciality Products Corporation
- BP on the sale of its PET feedstock plant in Decatur, Alabama to Indorama Ventures, and various oil & gas and petrochemical deals